{"id":3222,"date":"2021-11-08T22:42:00","date_gmt":"2021-11-08T22:42:00","guid":{"rendered":"http:\/\/staging.grindeks.eu\/grindeks-group-has-reached-record-high-turnover-and-profit-in-the-first-nine-months-of-2021\/"},"modified":"2022-07-05T06:10:10","modified_gmt":"2022-07-05T06:10:10","slug":"grindeks-group-has-reached-record-high-turnover-and-profit-in-the-first-nine-months-of-2021","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/grindeks-group-has-reached-record-high-turnover-and-profit-in-the-first-nine-months-of-2021\/","title":{"rendered":"Grindeks koncerns 2021. gada devi\u0146os m\u0113ne\u0161os sasniedzis rekordlielu apgroz\u012bjumu un pe\u013c\u0146u"},"content":{"rendered":"\n<p>Grindeks koncerna konsolid\u0113tie, provizoriskie finan\u0161u dati liecina, ka 2021. gada devi\u0146os m\u0113ne\u0161os koncerns sasniedzis rekordlielu apgroz\u012bjumu un pe\u013c\u0146u. \u0160aj\u0101 period\u0101 Grindeks koncerna apgroz\u012bjums sasniedza 168,9 milj. eiro, kas ir par 31,8 milj. eiro vai 23% vair\u0101k nek\u0101 2020. gada devi\u0146os m\u0113ne\u0161os. 2021. gada devi\u0146os m\u0113ne\u0161os koncerna pe\u013c\u0146a bija 27,6 milj. eiro, kas ir par 15,5 milj. eiro vai 2 reizes vair\u0101k nek\u0101 2020. gada devi\u0146os m\u0113ne\u0161os.<\/p>\n\n\n\n<p>2021. gada devi\u0146os m\u0113ne\u0161os liel\u0101ko p\u0101rdo\u0161anas apjomu veidoja medikamenti sirds un asinsvadu, k\u0101 ar\u012b centr\u0101l\u0101s nervu sist\u0113mas slim\u012bbu \u0101rst\u0113\u0161anai. Strauju p\u0101rdo\u0161anas k\u0101pumu sasniedza ar\u012b slimn\u012bcu segmenta medikamenti, ko pied\u0101v\u0101 AS Grindeks meitas uz\u0146\u0113mums Kalceks.<\/p>\n\n\n\n<p>2021. gada devi\u0146os m\u0113ne\u0161os koncerns sara\u017eoto produkciju eksport\u0113ja uz 97 valst\u012bm par kop\u0113jo summu 160,0 milj. eiro.<\/p>\n\n\n\n<p><strong>AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Dr. chem. Juris Hme\u013c\u0146ickis:&nbsp;<\/strong>\u201c2021. gada pirmajos devi\u0146os m\u0113ne\u0161os Grindeks koncerns ar p\u0101rliec\u012bbu turpin\u0101ja savu att\u012bst\u012bbu un izaugsmi, sasniedzot v\u0113sturiski augst\u0101kos pe\u013c\u0146as un apgroz\u012bjuma r\u0101d\u012bt\u0101jus. Tas pier\u0101da, ka m\u016bsu ieviest\u0101 biznesa strat\u0113\u0123ija un realiz\u0113t\u0101s p\u0101rmai\u0146as jau sniedz rezult\u0101tu. Esmu gandar\u012bts, ka m\u016bsu darbinieki ir vienoti un sp\u0113j operat\u012bvi piel\u0101goties main\u012bgajai un sare\u017e\u0123\u012btajai situ\u0101cijai gan Latvij\u0101, gan pasaul\u0113, nodro\u0161inot pacientus ar nepiecie\u0161amajiem medikamentiem. Man nav ne maz\u0101ko \u0161aubu, ka l\u012bdz \u0161im kop\u012bgi paveiktais darbs ir Grindeks izcil\u012bbas r\u0101d\u012bt\u0101js. M\u0113s savu izaugsmi tikai turpin\u0101sim un neapst\u0101simies pie jau sasniegt\u0101. Ticu, ka ikviens m\u0113r\u0137is t\u0101dam koncernam k\u0101 Grindeks ir sasniedzams.\u201d<\/p>\n\n\n\n<p>Koncerna gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2021. gada devi\u0146os m\u0113ne\u0161os kopum\u0101 bija 160,4 milj. eiro un ir palielin\u0101jies, sal\u012bdzinot ar 2020. gada devi\u0146iem m\u0113ne\u0161iem, par 31,1 milj. eiro vai par 24%.<br>Eiropas Savien\u012bbas un p\u0101r\u0113j\u0101s valst\u012bs gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2021. gada devi\u0146os m\u0113ne\u0161os sasniedza 85,2 milj. eiro, kas ir par 20,7 milj. eiro vai par 32% vair\u0101k nek\u0101 2020. gada devi\u0146os m\u0113ne\u0161os. P\u0101rdo\u0161anas apjoms 2021. gada devi\u0146os m\u0113ne\u0161os, sal\u012bdzinot ar 2020. gada devi\u0146iem m\u0113ne\u0161iem, Portug\u0101l\u0113 palielin\u0101j\u0101s 41 reizi, N\u012bderland\u0113 12 reizes, Apvienotajos Ar\u0101bu Emir\u0101tos 10 reizes, Bulg\u0101rij\u0101 4 reizes, Polij\u0101 3 reizes, Lielbrit\u0101nij\u0101 par 60%, Austrij\u0101 par 51%, bet Austr\u0101lij\u0101 par 43%.<\/p>\n\n\n\n<p>P\u0101rdo\u0161anas apjoms Krievij\u0101, p\u0101r\u0113j\u0101s NVS valst\u012bs un Gruzij\u0101 2021. gada devi\u0146os m\u0113ne\u0161os veidoja 75,1 milj. eiro, kas ir par 12,8 milj. eiro vai par 20% vair\u0101k nek\u0101 2020. gada devi\u0146os m\u0113ne\u0161os. Sal\u012bdzinot ar 2020. gada devi\u0146iem m\u0113ne\u0161iem, 2021. gada devi\u0146os m\u0113ne\u0161os Kirgizst\u0101n\u0101 p\u0101rdo\u0161anas apjoms palielin\u0101j\u0101s par 48%, Ukrain\u0101 par 44%, Moldov\u0101 par 39%, Baltkrievij\u0101 par 36%, Azerbaid\u017e\u0101n\u0101 par 33% un Gruzij\u0101 par 26%.<br>Grindeks produktu kl\u0101st\u0101 ir m\u016bsdien\u012bgi medikamenti sirds un asinsvadu, centr\u0101l\u0101s nervu sist\u0113mas, onkolo\u0123isko saslim\u0161anu un diab\u0113ta \u0101rst\u0113\u0161anai, savuk\u0101rt meitas uz\u0146\u0113rmums Kalceks pied\u0101v\u0101 medikamentus slimn\u012bcu segmentam. Izstr\u0101d\u0113 \u0161obr\u012bd ir 64 jauni Grindeks un 42 jauni Kalceks medikamenti.<\/p>\n\n\n\n<p>Grindeks koncernam \u013coti noz\u012bm\u012bga ir ar\u012b akt\u012bvo farmaceitisko vielu ra\u017eo\u0161ana, kas ir ar\u012b viena no koncerna b\u016btisk\u0101m priek\u0161roc\u012bb\u0101m farm\u0101cijas nozar\u0113. Pa\u0161reiz uz\u0146\u0113mums ra\u017eo 25 akt\u012bv\u0101s farmaceitisk\u0101s vielas. \u0160is segments palielina neatkar\u012bbu no izejvielu ra\u017eot\u0101jiem, t\u0101d\u0113\u013c uz\u0146\u0113mums izstr\u0101d\u0101 36 jaunas akt\u012bv\u0101s farmaceitisk\u0101s vielas. Akt\u012bvo farmaceitisko vielu pieejam\u012bba noz\u012bm\u0113 iesp\u0113ju efekt\u012bv\u0101k ra\u017eot gatavo z\u0101\u013cu formas koncerna ietvaros. Liel\u0101kais Grindeks akt\u012bvo farmaceitisko vielu eksports tiek veikts uz Eiropas Savien\u012bbas valst\u012bm, Jap\u0101nu, ASV un Kan\u0101du.<\/p>\n\n\n\n<p>2021. gada devi\u0146os m\u0113ne\u0161os AS Grindeks meitas uz\u0146\u0113mums Kalceks sasniedza spo\u017eus rezult\u0101tus. P\u0101rdo\u0161anas apjoms strauji pieauga, palielinot gan eksporta valstu skaitu, gan papla\u0161inot produktu kl\u0101stu. Kalceks produkti 2021. gada devi\u0146os m\u0113ne\u0161os tika p\u0101rdoti 50,8 milj. eiro apjom\u0101, kas ir par 19,1 milj. eiro vai par 60% vair\u0101k nek\u0101 2020. gada devi\u0146os m\u0113ne\u0161os. Kalceks medikamenti 2021. gada devi\u0146os m\u0113ne\u0161os tika eksport\u0113ti uz 75 valst\u012bm, un galven\u0101s no t\u0101m bija N\u012bderlande, Meksika, Lielbrit\u0101nija, Polija un Portug\u0101le.<\/p>\n\n\n\n<p><strong>AS Grindeks padomes priek\u0161s\u0113d\u0113t\u0101js Kirovs Lipmans:&nbsp;<\/strong>\u201cEs \u013coti nov\u0113rt\u0113ju Grindeks koncerna darbinieku milz\u012bgo ieguld\u012bjumu uz\u0146\u0113muma darb\u012bb\u0101. Koncerns att\u012bst\u0101s, ir uz starptautisku sadarb\u012bbu v\u0113rsts, un tas pal\u012bdz \u012bstenot ieceres un m\u0113r\u0137us. Esmu gandar\u012bts, ka m\u016bsu pacienti daudz\u0101s pasaules valst\u012bs sa\u0146em nepiecie\u0161amos medikamentus. Dom\u0101jot par koncerna n\u0101kotni, zinu, ka vienm\u0113r j\u0101veic p\u0101rdom\u0101tas invest\u012bcijas, kas uzlabo infrastrukt\u016bru, rada v\u0113l modern\u0101ku darba vidi un palielina uz\u0146\u0113muma ra\u017eo\u0161anas kapacit\u0101ti. \u0160\u0101di ieguld\u012bjumi ir nepiecie\u0161ami, lai m\u0113s sekm\u012bgi var\u0113tu konkur\u0113t pasaul\u0113 un lai m\u016bsu att\u012bst\u012bbas temps b\u016btu augst\u0101ks par vid\u0113jo, ko uzr\u0101da citi farm\u0101cijas tirgus sp\u0113l\u0113t\u0101ji.\u201d<\/p>\n\n\n\n<p>Lai neapst\u0101tos pie jau sasniegtajiem rezult\u0101tiem un ilgtermi\u0146\u0101 turpin\u0101tu pak\u0101penisku un stabilu koncerna izaugsmi, Grindeks devi\u0146os m\u0113ne\u0161os piev\u0113rsis \u012bpa\u0161u uzman\u012bbu ra\u017eo\u0161anas infrastrukt\u016bras uzlabo\u0161anai, kas sev\u012b ietver ar\u012b jaunu ra\u017eo\u0161anas iek\u0101rtu ieg\u0101di. \u0160obr\u012bd notiek jaunas gatavo z\u0101\u013cu formu ra\u017eo\u0161anas laboratorijas moderniz\u0101cijas darbi.<\/p>\n\n\n\n<p>\u0160ogad nosl\u0113gts jaun\u0101s r\u016bpn\u012bcas projekt\u0113\u0161anas l\u012bgums un veikti teritorijas labiek\u0101rto\u0161anas darbi. Jaun\u0101 r\u016bpn\u012bca tiks b\u016bv\u0113ta Latvij\u0101, R\u012bg\u0101, Asotes iel\u0101 12, vair\u0101kos posmos un ietvers komplic\u0113tus akt\u012bvo farmaceitisko vielu ra\u017eo\u0161anas procesus un m\u016bsdien\u012bgas tehnolo\u0123isk\u0101s iek\u0101rtas. T\u0101 b\u016bs liel\u0101k\u0101 farmaceitisk\u0101 ra\u017eotne Baltijas re\u0123ion\u0101 ar automatiz\u0113tiem un energoefekt\u012bviem risin\u0101jumiem.<\/p>\n\n\n\n<p><a href=\"https:\/\/infogram.com\/1pv11vgpy71zkjcx6yy7g6wm79brpdj1lrg\" target=\"_blank\" rel=\"noopener\">https:\/\/infogram.com\/1pv11vgpy71zkjcx6yy7g6wm79brpdj1lrg<\/a><\/p>\n\n\n\n<div class=\"infogram-embed\" data-id=\"_\/Do2SBiUuSy0sh6c45nHo\" data-type=\"interactive\" data-title=\"Grindeks-koncerna-rezultati-2021-9-MENESI-LV\"><\/div><script>!function(e,i,n,s){var t=\"InfogramEmbeds\",d=e.getElementsByTagName(\"script\")[0];if(window[t]&&window[t].initialized)window[t].process&&window[t].process();else if(!e.getElementById(n)){var o=e.createElement(\"script\");o.async=1,o.id=n,o.src=\"https:\/\/e.infogram.com\/js\/dist\/embed-loader-min.js\",d.parentNode.insertBefore(o,d)}}(document,0,\"infogram-async\");<\/script>\n","protected":false},"excerpt":{"rendered":"<p>Grindeks koncerna konsolid\u0113tie, provizoriskie finan\u0161u dati liecina, ka 2021. gada devi\u0146os m\u0113ne\u0161os koncerns sasniedzis rekordlielu apgroz\u012bjumu un pe\u013c\u0146u. \u0160aj\u0101 period\u0101 Grindeks koncerna apgroz\u012bjums sasniedza 168,9&#8230;<\/p>\n","protected":false},"author":3,"featured_media":6085,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3222","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/3222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=3222"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/3222\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/6085"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=3222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=3222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=3222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}